What is the Share Price of Brawn Biotech Ltd?

Brawn Biotech Ltd share price is ₹16.25 As on 09 May, 2025|14:56

Home
>
Stocks
>
Brawn Biotech Ltd

Brawn Biotech Ltd Share Price

Q: What is the Market Cap of Brawn Biotech Ltd?

The Market Cap of Brawn Biotech Ltd is ₹4.88 As on 09 May, 2025|14:56

Q: What is PE Ratio of Brawn Biotech Ltd?

The P/E ratio of Brawn Biotech Ltd is 0 As on 09 May, 2025|14:56

Q: What is PB Ratio of Brawn Biotech Ltd?

The PB ratio of Brawn Biotech Ltd is 1.15 As on 09 May, 2025|14:56

₹ 0.00 0 (0%)
Updated on 01-01-1970 5:30 AM

Stock Rating

BSE

Pros 2

Cons 8

Brawn Biotech Ltd Price Performance

Day's Low
₹0

Day's High
₹0

₹ 0

52-w low
₹0

52-w high
₹0

Day's open
₹0
Previous close
₹0
VWAP
₹0
Lower price band
₹0
Upper price band
₹0

Today's Market Action

Its last traded stock price on BSE was 16.25 down by -4.69%. The total volume of shares on NSE and BSE combined was 112 shares. Its total combined turnover was Rs 0.00 crores.

Brawn Biotech Ltd Medium and Long Term Market Action

The stock price of Brawn Biotech Ltd is down by -100% over the last one month. Don't forget to check the full stock price history in the table below.

Brawn Biotech Ltd Fundamentals

Market Cap (Cr): 4.88
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Brawn Biotech Ltd Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Brawn Biotech Ltd Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Brawn Biotech Ltd

Data not available.

Brawn Biotech Ltd FAQ's

What is Share Price of Brawn Biotech Ltd?

What is the Market Cap of Brawn Biotech Ltd?

What is PE Ratio of Brawn Biotech Ltd?

What is PB Ratio of Brawn Biotech Ltd?

What is the CAGR of Brawn Biotech Ltd?

How to Buy Brawn Biotech Ltd Share?

Can I buy Brawn Biotech Ltd from Samco?

How do I buy Brawn Biotech Ltd from Samco?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

Asset Light Business
The company operates a great asset light business with a high Asset turnover ratio of 32.92. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.
Zero Debt
The company has almost nil to negligible debt to equity ratio of 0.00. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.

Cons

Low Sustainable RoE
The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
Low Return on Capital Employed
The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
Poor Cash Flow Conversion
The business has very poor cash conversion ratio of only 2.17% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
Negative operating earnings and interest coverage
The company has a negative operating earnings and a negative Interest coverage ratio of -24.33 times which implies that the company has no operating earnings to pay for interest which is currently being paid out of capital and/or other income. This is extremely negative for shareholders.
Low Pricing Power & High Competition
The business has extremely low pricing power and is vulnerable to competitive pressure which can significantly impact shareholder returns.
Poor Capital Allocation
The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 97.12 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 277 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
Poor Corporate Governance
The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(09/05/2025)

Margin of Safety Index: High

0% People are bullish about Brawn Biotech Ltd

0 % People are bearish about Brawn Biotech Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %